On the other hand, the vascular endothelial growth factor (VEGF) can promote tumor angiogenesis and tumor growth (14), and simultaneous inhibition of S1PR1 and VEGFR can maximize the effect of anti-angiogenesis therapy and may become an effective treatment strategy for the treatment of renal cell carcinoma and other types of tumors (15). Here, S1PR1 is linked to neoplasm.